Affiliation:
1. Istituto di Genetica Biochimica ed Evoluzionistica, CNR, Pavia 27100, Italy,1 and
2. Departments of Microbiology,2
3. Chemistry,3 and
4. Biochemistry,4 La Trobe University, Bundoora, Victoria 3083, Australia
Abstract
ABSTRACT
All known DNA ligases catalyze the formation of a phosphodiester linkage between adjacent termini in double-stranded DNA via very similar mechanisms. The ligase family can, however, be divided into two classes: eubacterial ligases, which require NAD
+
as a cofactor, and other ligases, from viruses, archaea, and eukaryotes, which use ATP. Drugs that discriminate between DNA ligases from different sources may have antieubacterial activity. We now report that a group of arylamino compounds, including some commonly used antimalarial and anti-inflammatory drugs and a novel series of bisquinoline compounds, are specific inhibitors of eubacterial DNA ligases. Members of this group of inhibitors have different heterocyclic ring systems with a common amino side chain in which the two nitrogens are separated by four carbon atoms. The potency, but not the specificity of action, is influenced by the DNA-binding characteristics of the inhibitor, and the inhibition is noncompetitive with respect to NAD
+
. The arylamino compounds appear to target eubacterial DNA ligase in vivo, since a
Salmonella
Lig
−
strain that has been rescued with the ATP-dependent T4 DNA ligase is less sensitive than the parental
Salmonella
strain.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献